Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma

Inclusion Criteria

• •Males and females patients, aged \>3 years and \< 30 years;
• •Newly diagnosed of GBM, DIPG, diffuse brainstem glioma, diffuse spinal glioma, bilateral thalamic glioma, gliomatosis cerebri, anaplastic astrocytoma;
• •Patients undergone either surgery or biopsy only;
• •No prior chemotherapy and/or radiotherapy;
• •Life expectancy ≥ 4 weeks;
• •Karnofsky/Lansky ≥ 40 %;
• •Written informed consent obtained from the patient/parents or legal representative;
• •Adequate hematological function (leucocyte ≥ 2.0 x 10\^9/l -Hemoglobin ≥ 10 g/dl - platelet ≥ 50 x 10\^9 /l);
• •Adequate liver function (total bilirubin ≤ 2.5 x ULN - ALT/AST ≤ 5.0 x ULN);
• •Adequate renal function (serum creatinine ≤ 1.5 x ULN);
• •Adherence to trial treatment and compliance with the protocol